You are here:

Archived: Voriconazole (VFEND®)


Recommended for restricted use within NHS Scotland.


Voriconazole should be used only in suspected or confirmed cases of invasive aspergillosis; for infections caused by Fusarium spp and Scedosporium spp; or serious invasive candidiasis refractory to fluconazole. It should be administered primarily to immunocompromised patients with progressive, possibly life-threatening infections.

Drug Details

Drug Name: Voriconazole (VFEND®)
SMC Drug ID: 25/02
Manufacturer: Pfizer Ltd
Indication: Invasive aspergillosis
BNF Category:
Sub Category: 5.2 Antifungal Drugs
Submission Type: Full submission
Status: Restricted
Date Advice Published: 10 January 2003

Current Advice

Abbreviated Submission 13 December 2004